Sandoz Launches Generic Rivaroxaban 10–20 mg In Germany After Patent Win

Sandoz, the global leader in generics and biosimilars, has launched generic rivaroxaban in Germany in the 10 mg, 15 mg, and 20 mg strengths under the brand Rivaroxaban - 1 A Pharma®. This provides patients with a more affordable alternative to Bayer’s Xarelto®, supported by a list price advantage across all formulations. 

The launch follows successful litigation in Germany, where Sandoz was the first to challenge the relevant dosage patent. With the revocation of the patent on July 29, 2025, Sandoz gained the ability to introduce higher-dose formulations, expanding on its April 2024 launch of the 2.5 mg strength. This move positions Sandoz as the first company to offer a comprehensive rivaroxaban portfolio in Germany.

Thomas Weigold, Country President Germany, said, “After a 16-month delay, we can finally offer patients access to rivaroxaban in additional strengths. We are very pleased that we have successfully challenged the patent, because every day lost costs patients and the healthcare system in Germany unnecessary money.”

By joining all open-house discount agreements for rivaroxaban in Germany, Sandoz further strengthens affordability and access. The drug is indicated in adults for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of DVT and PE, and prevention of venous thromboembolism after orthopedic surgery. Pediatric indications include the treatment and prevention of venous thromboembolism.